Lourdes M Mendez MD PhD

Hematologic Oncology

Physician

35 Park StSmilow Cancer Hospital at Yale-New HavenNew Haven, CT 06519

Dr. Mendez is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mendez's full profile Already have an account?

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2008 - 2011
Albert Einstein College of MedicineClass of 2008

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CT State Medical License 2022 - 2026
MA State Medical License 2011 - 2023
NY State Medical License 2011 - 2013
American Board of Internal Medicine Hematology

Clinical Trials

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia Start of enrollment: 2018 Feb 08
ACTIVE_NOT_RECRUITING
PHASE1
Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2017 Sep 25
COMPLETED
PHASE2
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia Start of enrollment: 2019 Nov 06
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Roles: Contact, Principal Investigator

Publications & Presentations

PubMed

Cost-effectiveness of frontline eltrombopag with immunosuppressive therapy for severe aplastic anemia.
Satoko Ito, Kunal C Potnis, Ding Quan Ng, Kishan K Patel, Manraj Sra
Blood. Red Cells & Iron. 2026-06-01
Acute myeloid leukemia after myeloproliferative neoplasms: Real-world outcomes in the new treatment era in the United States.
Jan Philipp Bewersdorf, Rong Wang, Lourdes Mendez, Alain Mina, Luis E Aguirre
Cancer. 2026-05-01
1 citations
Comparative effectiveness of HMA with venetoclax vs intensive chemotherapy in AML with very high-risk cytogenetics.
Luis E Aguirre, Jan Philipp Bewersdorf, Yiwen Liu, Rory M Shallis, Leora Boussi
Blood Neoplasia. 2026-05-01